Technical Analysis for MCRB - Seres Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 3.14 0.96% 0.03
MCRB closed up 0.96 percent on Thursday, July 18, 2019, on 49 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical MCRB trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
20 DMA Support Bullish 0.00%
Doji - Bearish? Reversal 0.00%
Up 3 Days in a Row Strength 0.00%
20 DMA Support Bullish 0.96%
Pocket Pivot Bullish Swing Setup 0.96%
Crossed Above 20 DMA Bullish 3.63%
Pocket Pivot Bullish Swing Setup 3.63%
Outside Day Range Expansion 3.63%
Fell Below 20 DMA Bearish 12.54%

Older signals for MCRB ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Seres Therapeutics, Inc., a microbiome therapeutics platform company, focuses on the development of biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology, which has completed open label Phase Ib/2 clinical study for the prevention of further recurrences of Clostridium difficile infection (CDI). The company's product candidates in pre-clinical development comprise SER-262, an Ecobiotic microbiome therapeutic designed to be used following antibiotic treatment of primary CDI to prevent the initial recurrence of CDI; SER-287 to treat inflammatory bowel disease, including ulcerative colitis; and SER-155 to treat enteric pathogens, such as antibiotic-resistant bacteria. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Medicine Medical Specialties Autoimmune Diseases Inflammatory Bowel Disease Ulcerative Colitis Diarrhea Antimicrobial Resistance Digestive Diseases Clostridioides Difficile Clostridium Difficile Infection
Is MCRB a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 9.26
52 Week Low 2.02
Average Volume 653,459
200-Day Moving Average 5.7549
50-Day Moving Average 3.4009
20-Day Moving Average 2.9713
10-Day Moving Average 3.018
Average True Range 0.2857
ADX 15.06
+DI 19.625
-DI 16.7204
Chandelier Exit (Long, 3 ATRs ) 2.5729
Chandelier Exit (Short, 3 ATRs ) 3.1971
Upper Bollinger Band 3.2695
Lower Bollinger Band 2.6731
Percent B (%b) 0.78
BandWidth 20.072022
MACD Line -0.1037
MACD Signal Line -0.1715
MACD Histogram 0.0678
Fundamentals Value
Market Cap 127.21 Million
Num Shares 40.5 Million
EPS -2.42
Price-to-Earnings (P/E) Ratio -1.30
Price-to-Sales 17.96
Price-to-Book 4.50
PEG Ratio 0.03
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.47
Resistance 3 (R3) 3.45 3.31 3.42
Resistance 2 (R2) 3.31 3.23 3.33 3.40
Resistance 1 (R1) 3.23 3.18 3.27 3.25 3.38
Pivot Point 3.09 3.09 3.12 3.11 3.09
Support 1 (S1) 3.01 3.01 3.05 3.03 2.90
Support 2 (S2) 2.87 2.96 2.89 2.88
Support 3 (S3) 2.79 2.87 2.87
Support 4 (S4) 2.81